Literature DB >> 5673232

Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma).

M L Samuels, P Sullivan, C D Howe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5673232     DOI： 10.1002/1097-0142(196809)22:3<525::aid-cncr2820220306>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  8 in total

1.  Possible role of hormones in treatment of metastatic testicular teratomas: tumour regression with medroxyprogesterone acetate.

Authors:  H J Bloom; W F Hendry
Journal:  Br Med J       Date:  1973-09-15

Review 2.  Update in cancer chemotherapy: genitourinary tract cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1987-12       Impact factor: 1.798

3.  Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epithelization in rabbits.

Authors:  W Lenco; M Mcknight; A S Macdonald
Journal:  Ann Surg       Date:  1975-01       Impact factor: 12.969

Review 4.  Current status of the management of patients with endocrine-sensitive tumors. II. Carcinoma of the prostate, endometrium, thyroid, kidney and miscellaneous tumors.

Authors:  L G Crowley; S A Duwe
Journal:  Calif Med       Date:  1969-02

5.  Observations with Depo-Provera (medroxyprogesterone) in the management of renal tumours.

Authors:  I Romics; D Répássy
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

6.  Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer.

Authors:  H J Bloom
Journal:  Br J Cancer       Date:  1971-06       Impact factor: 7.640

7.  Hormonal treatment of metastases of renal carcinoma.

Authors:  B van der Werf-Messing; H A van Gilse
Journal:  Br J Cancer       Date:  1971-09       Impact factor: 7.640

8.  The use of progestogen in the treatment of metastatic carcinoma of the kidney and uterine body.

Authors:  C H Paine; F W Wright; F Ellis
Journal:  Br J Cancer       Date:  1970-06       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.